Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 17/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.53 |
| ▸ | AR | P10275 | 3/20 | 0.53 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.48 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.48 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.48 |
| ▸ | PDE4A | P27815 | 2/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3870140 | 0.81 | PGR (1.00) | PGRNR3C1ARNR3C2 | |
| SCHEMBL3526645 | 0.81 | PGR (1.00) | PGRNR3C1ARNR3C2PDE3B | |
| SCHEMBL5226807 | 0.80 | PGR (0.75) | PGRPDE3BPDE3APDE4APDE4B | |
| SCHEMBL3870856 | 0.76 | PGR (1.00) | PGRNR3C1 | |
| SCHEMBL3518135 | 0.73 | PGR (1.00) | PGRARPDE3BPDE3A | |
| SCHEMBL6897859 | 0.73 | PGR (1.00) | PGRNR3C1AR | |
| SCHEMBL3872351 | 0.72 | PGR (0.69) | PGRNR3C1ARNR3C2 | |
| SCHEMBL25944404 | 0.72 | PGR (0.71) | PGRPDE3BPDE3APDE4APDE4B | |
| SCHEMBL1223269 | 0.72 | PGR (0.67) | PGR | |
| SCHEMBL3522682 | 0.71 | PGR (0.70) | PGRARPDE3BPDE3APDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645761-B2 | Indoline derivatives | WYETH (US) | 2010-01-12 | — | — | US | claimed |
| US-20070259944-A1 | Indoline derivatives | WYETH (US) | 2007-11-08 | — | — | US | claimed |
| US-7253203-B2 | Indoline derivatives | WYETH (US) | 2007-08-07 | — | — | US | claimed |
| EP-1175398-B1 | INDOLINE DERIVATIVES AS PROGESTERONE ANTAGONISTS | WYETH CORP (US) | 2007-07-11 | — | — | EP | claimed |
| US-20060160882-A1 | Indoline derivatives | WYETH (US) | 2006-07-20 | — | — | US | claimed |
| CN-1141295-C | Indoline derivatives as progesterohe antagonists | �Ʒ� | 2004-03-10 | — | — | CN | claimed |
| US-20030220388-A1 | Amides such as 5-(3-Nitrophenyl)-1,3-dihydro-indol-2-one, used as antiprogesterones, contraceptives, for hormone replacement therapy during menopause and as anticarcinogenic agents | WYETH | 2003-11-27 | — | — | US | claimed |
| US-6544970-B2 | Administering in a first phase of a progestational agent (levonorgestrel or ethinylestradiol) and in a second phase an antiprogestin that is an indolinone derivative, especially a 3-spiroalkylene derivative | WYETH | 2003-04-08 | — | — | US | claimed |
| US-20030050288-A1 | Cyclic regimens utilizing indoline derivatives | WYETH | 2003-03-13 | — | — | US | claimed |
| JP-2002543183-A | — | — | 2002-12-17 | — | — | JP | claimed |
| JP-2002543158-A | — | — | 2002-12-17 | — | — | JP | claimed |
| US-6462032-B1 | Cyclic regimens utilizing indoline derivatives | WYETH | 2002-10-08 | — | — | US | claimed |
| US-20020086874-A1 | Indoline derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-07-04 | — | — | US | claimed |
| CN-1350523-A | Indoline derivatives as progesterone antagonists | AMERICAN HOME PROD (US) | 2002-05-22 | — | — | CN | claimed |
| CN-1349416-A | Contraceptive compositions contaiing indoline derivatives and progestational agents | AMERICAN HOME PROD (US) | 2002-05-15 | — | — | CN | claimed |
| EP-1175398-A1 | INDOLINE DERIVATIVES AS PROGESTERONE ANTAGONISTS | American Home Products Corporation (US) | 2002-01-30 | — | — | EP | claimed |
| EP-1173212-A1 | CONTRACEPTIVE COMPOSITIONS CONTANING INDOLONE DERIVATIVES AND PROGESTATIONAL AGENTS | American Home Products Corporation (US) | 2002-01-23 | — | — | EP | claimed |
| WO-2000066167-A1 | CONTRACEPTIVE COMPOSITIONS CONTAINING INDOLINE DERIVATIVES AND PROGESTATIONAL AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-11-09 | — | — | WO | claimed |
| WO-2000066556-A1 | INDOLINE DERIVATIVES AS PROGESTERONE ANTAGONISTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-11-09 | — | — | WO | claimed |
| US-7645761-B2 | Indoline derivatives | WYETH (US) | 2010-01-12 | — | — | US | disclosed |
| US-20070259944-A1 | Indoline derivatives | WYETH (US) | 2007-11-08 | — | — | US | disclosed |
| US-7253203-B2 | Indoline derivatives | WYETH (US) | 2007-08-07 | — | — | US | disclosed |
| EP-1175398-B1 | INDOLINE DERIVATIVES AS PROGESTERONE ANTAGONISTS | WYETH CORP (US) | 2007-07-11 | — | — | EP | disclosed |
| US-7084168-B2 | Indoline derivatives | WYETH (US) | 2006-08-01 | — | — | US | disclosed |
| US-20060160882-A1 | Indoline derivatives | WYETH (US) | 2006-07-20 | — | — | US | disclosed |
| CN-1141295-C | Indoline derivatives as progesterohe antagonists | �Ʒ� | 2004-03-10 | — | — | CN | disclosed |
| US-20030220388-A1 | Amides such as 5-(3-Nitrophenyl)-1,3-dihydro-indol-2-one, used as antiprogesterones, contraceptives, for hormone replacement therapy during menopause and as anticarcinogenic agents | WYETH | 2003-11-27 | — | — | US | disclosed |
| US-6608068-B2 | Substituted indoline derivative compounds which are antagonists of the progesterone receptor; contraceptives; antineoplastic agents | WYETH | 2003-08-19 | — | — | US | disclosed |
| US-6544970-B2 | Administering in a first phase of a progestational agent (levonorgestrel or ethinylestradiol) and in a second phase an antiprogestin that is an indolinone derivative, especially a 3-spiroalkylene derivative | WYETH | 2003-04-08 | — | — | US | disclosed |
| US-20030050288-A1 | Cyclic regimens utilizing indoline derivatives | WYETH | 2003-03-13 | — | — | US | disclosed |
| US-6462032-B1 | Cyclic regimens utilizing indoline derivatives | WYETH | 2002-10-08 | — | — | US | disclosed |
| US-20020086874-A1 | Indoline derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-07-04 | — | — | US | disclosed |
| CN-1350523-A | Indoline derivatives as progesterone antagonists | AMERICAN HOME PROD (US) | 2002-05-22 | — | — | CN | disclosed |
| US-6391907-B1 | ANTICANCER AGENTS; CONTRACEPTIVES | AMERICAN HOME PRODUCTS CORPORATION | 2002-05-21 | — | — | US | disclosed |
| CN-1349416-A | Contraceptive compositions contaiing indoline derivatives and progestational agents | AMERICAN HOME PROD (US) | 2002-05-15 | — | — | CN | disclosed |
| EP-1175398-A1 | INDOLINE DERIVATIVES AS PROGESTERONE ANTAGONISTS | American Home Products Corporation (US) | 2002-01-30 | — | — | EP | disclosed |
| WO-2000066556-A1 | INDOLINE DERIVATIVES AS PROGESTERONE ANTAGONISTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-11-09 | — | — | WO | disclosed |
| WO-2000066556-A1 | INDOLINE DERIVATIVES AS PROGESTERONE ANTAGONISTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259944-A1 | Indoline derivatives | PGR, GNRHR, PRLHR | PGR 1/4885NR3C1 45/4885AR 11/4885 |
| US-20020086874-A1 | Indoline derivatives | PGR, GNRHR, PRLHR | PGR 1/4885NR3C1 39/4885AR 4/4885 |
| US-20060160882-A1 | Indoline derivatives | PGR, GNRHR, PRLHR | PGR 1/4885NR3C1 45/4885AR 11/4885 |
| US-20030220388-A1 | Amides such as 5-(3-Nitrophenyl)-1,3-dihydro-indol-2-one, used as antiprogesterones, contraceptives, for hormone replacement therapy during menopause and as anticarcinogenic agents | PGR, CYP19A1, PGRMC1 | PGR 1/4885NR3C1 36/4885AR 18/4885 |
| US-20030050288-A1 | Cyclic regimens utilizing indoline derivatives | PRLHR, GNRHR, BRCA1 | PGR 5/4885NR3C1 178/4885AR 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.